COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D HC QHC Q Vitamin CV.C ZincZn PVP-IPVP-I FLVFLV REGNR2 LY-CoVLY RemdesivirRMD
HCQ study #180 of 259
11/6 Pre-Exposure Prophylaxis study (treated before exposed to the virus)
Mathai et al., J. Marine Medical Society, doi:10.4103/jmms.jmms_115_20 (Peer Reviewed)
Hydroxychloroquine as pre-exposure prophylaxis against COVID-19 in health-care workers: A single-center experience
Source   PDF   Share   Tweet
90% reduction in cases with HCQ pre-exposure prophylaxis. Retrospective 604 healthcare workers.

Mathai et al., 11/6/2020, retrospective, India, South Asia, peer-reviewed, 3 authors.
risk of COVID-19 case, 89.5% lower, RR 0.10, p < 0.001, treatment 10 of 491 (2.0%), control 22 of 113 (19.5%).
risk of COVID-19 case, 88.5% lower, RR 0.12, p < 0.001, treatment 5 of 491 (1.0%), control 10 of 113 (8.8%), symptomatic.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. For an individual study the most serious outcome may have a smaller number of events and lower statistical signficance, however this provides the strongest evidence for the most serious outcomes when combining the results of many trials.
Details of all 259 studies    Meta analysis
Please send us corrections, updates, or comments.
Submit